Quotient Bioresearch’s The Old Glassworks is expected to produce radiolabelled compounds for use in both pre-clinical and clinical settings, for its pharmaceutical, biotechnology and agrochemical clients, offering a bespoke service for the custom synthesis of carbon-14 and tritium labelled compounds.
Quotient Bioresearch, through its The Old Glassworks, is expected to serve over 250 clients including its existing Europe, the US and Japan. Its chemists are expected to work closely with the company’s metabolism and clinical research groups to deliver clients the solution for their carbon-14 enabled drug development needs, reducing complexity, cost and timelines.
Paul Cowan, chairman and CEO of Quotient Bioresearch, said: “With the opening of the new Cardiff facility, we have made an investment to support the product development needs of our pharmaceutical, biotechnology and agrochemicals clients.
“We have invested in technology that is expected to make the business operate sustainably and allow our chemists to deliver quality products to our clients. The opening of The Old Glassworks is expected to allow us to continue to expand.”
Stephen Lewinton, managing director of chemistry and metabolism at Quotient Bioresearch, said: “The new facility allows us to build on our fully integrated carbon-14-enabled drug development services (including Synthesis-to-ClinicTM). Quotient remains focused on meeting the needs of its clients for cost-effective custom radiosynthesis services.”